PRESS INFORMATION BUREAU GOVERNMENT OF INDIA पत्र सुबना कार्यातय भारत सरकार

Width: 27.09 cms, Height: 9.76 cms, a4r, Ref: pmin.2014-06-26.19.26 Wednesday 25th June 2014, Page: 10 DNA, Mumba

Fourth-largest domestic drug maker in terms of revenue plans to enter new geographies, expand product portfolio ns acou **ns in Ind**

oumonty Kanungo @SoumontyK

strategic fit companies in India which are a ence. It is also open to acquire nies in Japan, where it has a pres phies, and is scouting for compais looking to enter new geogra**dumbai:** Pharma major Lupin

na, Korea, Turkey and Brazil." in markets such as Russia, Chi-One of them is to have presence tor, Lupin, told dna, "We have identified a few growth areas. Nilesh Gupta, managing direc-

5-7 years, and has managed to ento build a presence in Brazil for ter Mexico equisition. The company has been trying through an

> ger in size than the Indian mar-ket and is growing faster than kets like these," Gupta said. is a profitable market, much bigit is important for us to be in mar-India. On long-term perspective, "The Latin American market

regions and therapeutic areas. pany that will help it enter newer in the complex injectable space in Japan, in India Lupin may be interested in acquiring a com-While it is scouting for a firm

regional player that has a presare not strong. Also, we are not ence in geographies where we "In India, we would look at a

presence in injectable space. All present in areas such as cancer, dermatology, and have limited

1 ROW Booster dose upin geographical revenue break-up in PVI4 44 **lag**],]4 Share price on NSE in ₹ 御祭堂 Charles Carlos Jun 24 1009.20 1025 955 0661 920

pies, as well as biosimilars and fill gaps in technology and therathese can be looked into," he said. Gupta said Lupin also wants to

jectables and dermatology. folio in inhalation, complex in-

wards developing a product portdrug discovery. It working tothe US in terms of products portis to acquire brands in the US. We had faced some real challenges in "The priority of the company

longer term, we will do it through our own products." Last year, the mi BV to expand into patented company acquired Netherlands-based injectable company Nanosition in near term, but in the the idea is to do it through acquidecline on the branded side. So generics side, we actually saw a folio. While we are strong on the

us the right technology. We are we have seriously started looking at injectables. Nanomi BV brings also putting together the rest of products. make a dent into the space," Gupwill take at least 3-4 years to the portfolio for injectables. It "It is only last two years that

New avenues

build a presence in Brazil for 5-7 areas. Last year, the company in Japan, in India Lupin may be interested in acquiring a expand into patented products Injectable company Nanomi BV to acquired Netherlands-based newer regions and therapeutic company that will help it enter While it is scouting for a firm in the complex injectable space The company has been trying to technology and theraples, as well Lupin also wants to fill gaps in rears, and has managed to enter lexico through an acquisition.

850 885

as blosimilars.

ta said.

ć